Related Experiment Video
Updated: May 21, 2026
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Primary care physicians' knowledge of and experience with pharmacogenetic testing
S B Haga1, W Burke, G S Ginsburg
1Institute for Genome Sciences & Policy, Duke University, Durham, NC 27708, USA. susanne.haga@duke.edu
Clinical Genetics
|June 16, 2012
Summary
Primary care physicians (PCPs) see value in pharmacogenetic (PGx) testing but lack the confidence and training to use it. Addressing knowledge gaps is crucial for integrating PGx testing into routine patient care.
Area of Science:
- Pharmacogenomics
- Genetics in Medicine
- Primary Care Practice
Background:
- Pharmacogenetic (PGx) testing is expanding, with primary care physicians (PCPs) expected to be key users.
- Understanding PCP training, familiarity, and attitudes is vital for identifying barriers to PGx test adoption.
Purpose of the Study:
- To assess the current training, familiarity, and attitudes of PCPs regarding pharmacogenetic testing.
- To identify barriers to the uptake of PGx testing among PCPs.
Main Methods:
- A national survey was conducted among a sample of primary care physicians.
- Data collected included demographics, awareness of PGx testing, perceived value, comfort level, and prior education.
Main Results:
- The majority of PCPs have heard of PGx testing and believe it will inform drug response.
- Only 13% of PCPs felt comfortable ordering PGx tests, and nearly 25% reported no formal education in pharmacogenetics.
- PCPs recognize their knowledge gaps despite envisioning a significant role in delivering PGx testing.
Conclusions:
- Primary care practitioners acknowledge the importance of PGx testing but face significant knowledge and experience deficits.
- Developing practical guidance and educational tools for PCPs is a high priority to facilitate the integration of PGx testing.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...